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Background: Early detection and treatment of non-invasive neoplasms can effectively reduce the incidence of
advanced gastric carcinoma (GC), but only when the lineage is continuous between non-invasive and advanced
tumours. Although a fraction of non-invasive neoplasms progress to invasive GC, it is difficult to identify individual
progression-prone non-invasive neoplasms. To classify non-invasive gland-forming gastric neoplasms into clusters
of different levels of progression risk, we applied mucin phenotyping and genomic DNA microarray analyses to
intramucosal gland-forming gastric neoplasms.
Methods: Formalin-fixed, paraffin-embedded tissues from 19 non-invasive and 24 invasive gland-forming neoplasms
were obtained via endoscopic submucosal dissection or surgical excision. According to the Vienna classification,
intramucosal neoplasms were classified as low-grade or high-grade non-invasive neoplasms (LGNs [category 3]
and HGNs [category 4], respectively) or invasive carcinomas (intramucosal GCs and mucosal parts of submucosal
or deeper GCs [category 5]). Neoplastic lesions were characterized by mucin phenotypes determined using monoclonal
antibodies against MUC2, MUC5AC, MUC6, and CD10. Genomic DNA samples from mucosal neoplasms were subjected
to array-based comparative genomic hybridization and subsequent unsupervised, hierarchical clustering with selected
large-sized genes.
Results: There was no significant difference in mucin phenotype between HGNs/LGNs and invasive carcinomas.
The clustering classified samples into stable, unstable, and intermediate. The histological tumour grade or
mucin phenotype of non-invasive neoplasms did not correlate with the clustering results. Each cluster may
represent an independent lineage of different outcome because the size distribution of non-invasive tumours
among the 3 clusters almost overlapped. In contrast, the unstable cluster alone included invasive carcinomas.
Conclusions: These findings suggest that the outcome of individual tumours is not stochastically determined
but can be predicted from the genomic copy-number profile even at the non-invasive stage. Non-invasive
neoplasms of the unstable clusters, which accounted for 21% of non-invasive neoplasms, may progress to
invasive carcinomas, whereas those of stable cluster may not.
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Gastric carcinoma (GC) is one of the most common malig-
nant tumours and has the fourth highest mortality rate
worldwide [1]. Endoscopic examination for early GC de-
tection has been refined by recent technical developments
such as narrow band imaging and magnifying observation
endoscopes [2-5]. Therefore, endoscopically resected, non-
invasive gland-forming gastric neoplasms are more
frequently encountered during pathological examinations.
Increased detection and treatment of non-invasive neo-
plasms may contribute to a reduction of GC-associated
mortality, but only if the genetic lineage is continuous
from the non-invasive neoplasms to advanced GCs.
Regarding the outcome of gastric non-invasive neo-
plasms, Western and East Asian follow-up studies con-
ducted between 1987 and 2008 reported that low-grade
neoplasms (LGNs) and high-grade neoplasms (HGNs)
progressed to invasive carcinomas at frequencies of
0–23% and 10–85%, respectively [6-15]. These varying
incidences may reflect varied pathological criteria for
differentiating intramucosal neoplasms and different mean
follow-up times. After standardizing the criteria according
to an international consensus (Vienna classification), re-
cent follow-up studies indicated that approximately 10%
of LGNs progressed to invasive carcinomas [12,15].
However, it is difficult to specify individual progression-
prone non-invasive neoplasms without a progression-
specific marker. When the morphological grade was used
as such a marker, long-term follow-up studies demon-
strated that almost a third of HGNs remained unchanged
despite their high-grade histology [12]. Therefore, histo-
logical grade has limited value when assessing the progres-
sion risk of individual tumours. In the present study, we
used 2 more specific lineage markers: mucin phenotype, as
a cell type-specific gene expression marker, and genomic
DNA copy-number profile, as a genetic lineage marker.
The mucin phenotype, determined by the expression
pattern of mucin core proteins (encoded by the MUC
gene family) and another protein, CD10, expressed in
the brush border of small intestinal enterocytes, is used
to classify cell types as gastric and intestinal [16,17]. In
normal tissues, different phenotypes are determined epi-
genetically, and stably inherited from cell to cell. This
heritability of phenotypes can be used in lineage-specific
progression risk assessment studies. Previous studies re-
ported that non-invasive neoplasms commonly progressed
to invasive adenocarcinoma in the gastric lineages, but
rarely in the intestinal lineages [14,16-18]. However, dur-
ing tumour progression from an early to an advanced
stage, metaplastic intestinal-type expression [19,20] and/
or the progression-related loss of gastric-type expression
[17,20] can occur.
As a genetic lineage marker, we focused on overall gen-
omic DNA copy-number profiles, which are determinedby array-based comparative genomic hybridization (aCGH).
These profiles are unique for individual neoplasms
because they include random alterations of genes that
are non-essential for carcinogenesis and accumulate
over time based on genetic instability. The samples were
classified based on overall similarities in the DNA copy-
number profiles by an unsupervised hierarchical cluster
analyses.
In the present study, we compared two lineage analyses
using identical non-invasive and invasive gastric tumours
to investigate whether they enabled the prediction of the
progression risks of individual non-invasive gastric neo-
plasms. The results indicated that the genetic, but not the
phenotypic markers could predict the progression risk of
individual non-invasive gastric neoplasms.
Methods
Tissues samples
The Institutional Review Board on Medical Ethics at
Shiga University of Medical Science approved the study
on the condition that the materials used remained an-
onymous (Permission number: 14-57-5 on 16 November
2013). Written informed consent was not required for
this retrospective study that detected acquired genomic
changes in archival materials alone.
Formalin-fixed, paraffin-embedded (FFPE) tissues from
19 non-invasive and 24 invasive intramucosal gastric neo-
plasms, which were endoscopically or surgically resected
from 38 patients, were obtained between 2009 and 2013.
Of the invasive carcinomas, tumours comprising a ≥50%
tubular-forming component, which included at least a
portion of well-differentiated tubular area, were used in
this study. Intramucosal lesions were classified histologi-
cally into 3 groups according to the Vienna classification
[21]: group A (non-invasive low grade neoplasia [category
3]), group B (non-invasive high grade neoplasia [category
4]), and group C (invasive tubular adenocarcinoma [cat-
egory 5]), as shown in Figure 1. Group C was subdivided
into Cm (intramucosal invasive carcinoma) and Cd (intra-
mucosal part of submucosal or deeper invasive carcin-
oma). Pathological stages were determined according to
the Japanese classification of GC [22].
Immunohistochemistry
Mucin phenotypes were evaluated immunohistochemi-
cally using monoclonal antibodies (Novocastra, Newcastle,
UK) against the goblet cell mucin MUC2 (Ccp58; 1:100
dilution), gastric-foveolar mucin MUC5AC (CLH2; 1:100),
pyloric-gland mucin MUC6 (CLH5; 1:100), and brush
border CD10 (56C6; 1:100). Immunohistochemical stain-
ing was performed using an automated Ventana Discovery
XT system (Tucson, AZ, USA) with heat pre-treatment
and a universal DAB detection kit (Ventana). The used
sections included areas corresponding to those obtained
Figure 1 Representative haematoxylin and eosin (H & E) images of neoplasms in groups A, B, and C. (a) Group A (Vienna category 3:
non-invasive low-grade neoplasia with dark, slender nuclei); (b) group B (Vienna category 4: non-invasive high-grade neoplasia with ovoid vesicular
nuclei and prominent nucleoli (carcinoma in situ)); (c) group C (Vienna category 5: invasive neoplasia with pleomorphic, hyperchromatic nuclei and
structural atypia). The inset in each image shows a high power view.
Figure 2 Representative H&E images and different marker
expressions. (a) Low-grade non-invasive neoplasia (group A)
complete intestinal type (I-type). Tumour glands are rarely and frequently
positive for MUC2 and CD10, respectively, and negative for MUC5AC and
MUC6. In contrast, residual normal glands are positive; (b) High-grade
non-invasive neoplasia (group B), complete gastric type (G-type). Tumour
glands are positive for MUC5AC and MUC6, and negative for MUC2 and
CD10; (c) invasive intramucosal tubular adenocarcinoma (group C),
gastrointestinal type (GI-type). Tumour glands are positive for MUC5AC,
MUC6, and MUC2, and negative for CD10.
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the Genomic DNA extraction methods).
The extent of MUC2, MUC5AC, MUC6 and CD10 ex-
pression was scored according to the percentage of stained
neoplastic cells as follows: (−), 0% to <5% positive cells; (+),
some positive cells, (≥5% to <30%); (++), well-defined areas
of positive cells (≥30% to <60%) and (+++), extensive areas
of positive cells (≥60%). According to the gastric markers
(MUC5AC and/or MUC6) and intestinal markers (MUC2
and/or CD10) scores, each neoplasm was phenotypically
classified as pure gastric type (G-type), mixed type (GI-
type), complete intestinal type (I-type) or null type (N-type)
as described previously [17] (Figure 2).
Genomic DNA extraction
Tumour and normal gland (reference) samples were ob-
tained from 5-micron-thick tissue sections using a laser mi-
crodissection system (LMD6000; Leica Microsystems,
Wetzlar, Germany). Each sample was dissected from an
area of ≥6 mm2. In tumour samples, neoplastic cells com-
prised 90% of the total cell count. These cells were then
digested in a 200-mg/mL proteinase K (P2308, Sigma-
Aldrich, St. Louis, USA) solution for 70 ± 2 h at 37°C prior
to the phenol/chloroform DNA extraction. Corresponding
tumour areas were assessed for the immunohistochemical
staining of mucin and other markers as described above.
DNA quality was assessed based on the A260/A280 ratio
(cut-off. >1.5) and A260/A230 ratio (cut-off. > 1.0) and by
the presence or absence of double-stranded DNA.
Whole genome amplification (WGA)
Sample DNA was amplified using the GenomePlex
Whole Genome Amplification Kit (WGA2 Kit; Sigma,
St. Louis, MO, USA) according to the manufacturer’s
protocol [23].
Array CGH
For genomic DNA analysis, a 60-mer oligonucleotide
aCGH (Agilent, Santa Clara, CA, USA) was used, accord-
ing to the manufacturer’s instructions [24]. The GenomicDNA Enzymatic Labelling Kit (version 7.2, 2012) was used
for small-size LGNs, whereas the Genomic DNA ULS La-
belling Kit (non-enzymatic labelling) was used for massive
and invasive cancer samples (protocol CGH_107_Sep09
and Grid: 021924_D_F_20100501 and protocol CGH_
107_Sep09 and Grid: 021924_D_F_20111015). Briefly,
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Cy3, respectively, followed by competitive hybridization to
microarrays (SurePrint G3 CGH Microarray 8 × 60 K,
GPL10152 62,976 probes). The tumour-to-reference fluor-
escence intensity ratio (T/R) was calculated from the
hybridized array images obtained using a DNA microarray
scanner (Feature Extraction software 10.7.3.1). Agilent
CGH Analytics Software was used to visualize, detect, and
analyse chromosomal patterns within the microarray pro-
files. The UCSC Genome Browser was applied according to
the latest resource content: hg19 assembly - Design ID
021429 (GRCh Build 37). Copy-number alterations (CNAs)
were defined as gains and losses when base 2 logarithm
of the T/R ratios were >0.3219 and <−0.3219, respect-
ively. The microarray data were registered in the Gene
Expression Omnibus (GEO) database (Accession number:
GSE60116).
Clustering algorithm
To enhance the signal-to-noise ratios in hybridization ana-
lyses, we averaged the T/R ratio of the probes within each
gene prior to performing cluster analyses. To classify sam-
ples based solely on genome-wide resemblances in the gene
copy-number gain/loss patterns, unsupervised hierarchical
cluster analyses were performed using a free software
programme (Cluster 3.0, version 1.52 and TreeView, ver-
sion 1.1.6r2) [25,26]. We selected genes by size; for larger
genes, more probes were included within the genes, and
the noise cancelling effect was expected to increase by aver-
aging the probe data. We attempted repeated clustering
using genes ranging from 372 genes containing ≥10 probes
to 9,615 genes containing ≥2 probes. The optimal gene size
was determined as the largest gene that fulfilled the fol-
lowing standards: first, ≥2 identical tumour samples were
located at neighbouring positions in the tree diagram of
cluster analyses because these samples have more com-
mon CNAs during carcinogenesis than any other tumours
[27]; second, each cluster’s sample constitution becomes
constant. The clustering condition was set to a complete
linkage (maximum of distance metric on similarities) and
the uncentred correlation distance (distance measures
based on modified Pearson’s correlation).
Genes exhibiting significantly different CNAs between clusters
We applied Welch’s t-test with Bonferroni correction be-
tween the averaged log2 (T/R) values (reflecting averaged
copy-numbers) of total aggressive and total stable tumour
samples for 14,753 protein-encoding genes (Office Excel
2013; Microsoft, Redmond, WA, USA).
Microarray data validation by quantitative polymerase
chain reaction (PCR)
Remaining DNA samples (tumour and reference) from 8
randomly selected sample pairs, used in aCGH analyses,were subjected to quantitative PCR. Primers (Additional
file 1: Table S1) were designed using Primer3 software
(http://bioinfo.ut.ee/primer3-0.4.0/). As an internal stand-
ard, we used one set of primers that was specific for
chr15:51481794–51481853 and selected from the genomic
DNA portion with few gains or losses. PCR was carried
out in a final volume of 10 μL using the LightCycler Nano
following the manufacturer’s instructions (Roche, Basel,
Switzerland). Briefly, the reaction mixture consisted of
500 nM of each forward and reverse primer, 10 ng of
DNA sample and 1 × FastStart Essential DNA Green
Master mix (Roche). PCR was performed in duplicate
using the following conditions: denaturing at 95°C for
10 min, followed by 45 cycles of PCR at 95°C for 10 s,
annealing and elongating at 60°C for 30 s. Cq value was
determined by selecting the second derivative maximum
method equipped on the LightCycler Nano.Statistical analysis
The differences in CNA for each gene and in phenotypic
expression among groups A, B, and C were statistically
assessed in an unequal sample-size t-test (Welch’s t-test)
[28]. A bilateral p-value of ≤0.05 was considered statisti-
cally significant. For multiple comparisons, the t test was
adjusted subsequently using the Bonferroni correction
[23,28] (Microsoft Office Excel 2013). To assess trend
differences in either mucin phenotypes or CNA accumu-
lations between the 2 groups, a Fisher’s exact test (2 × 2
contingency tables) or the Cochran–Armitage test (for
2 × κ contingency tables) was performed (Excel Statistics
for Windows, 2012 Edition, Social Survey Research
Information Co., Ltd., Tokyo, Japan).Results
Histology and mucin phenotypic expressions among
groups A, B, and C
Of the 43 tumours, 7 were categorized as group A, 12 as
group B, 8 as group Cm, and 16 as group Cd. The Cd
group tumours comprised 3 submucosal and 13 advanced
cancers. The average ages of patients did not differ be-
tween groups A and B or groups Cm and Cd (p = 0.48,
p = 0.50, respectively), but they were higher in group C
than in group A/B (p = 0.0002). Other clinicopathological
features are summarized in Table 1 and Additional file 1:
Tables S2a and S2b. Multiple non-invasive neoplasms that
incidentally coexisted with main lesions were also analysed
and marked as pairs 1–5.
Concurrent intramucosal lesions sampled from 5 pa-
tients were comprised 5 tumour pairs: A3–A7, B5–B12,
A4–B11, Cd1–Cd8 and A2–Cd12. The distance between
the lesions in each pair ranged from 1.5–7 cm.
The tumour sizes of the intra-mucosal lesions in groups
A, B, Cm and Cd were 5.7 mm (range, 2–12 mm), 9.4 mm
Table 1 Clinicopathological features of tumour samples
in groups A, B, and C according to the Vienna
classification
Group Group A Group B Group C
Cm Cd
Sex (M:F) 4:3 7:5 6:2 12:4
Age (years)
Range 59 – 81 41 - 77 59 – 92 64 – 88
Mean ± SD 66.5 ± 10.0 62.1 ± 9.7 74.25 ± 10.4 77.1 ± 7.4
Size (mm)
Range 2 – 12 3 – 30 15 – 40 15 – 100
Mean ± SD 5.7 ± 3.1 9.4 ± 7.9 27.1 ± 7.8 51.1 ± 27.1
Cm, intramucosal invasive carcinoma; Cd, intramucosal part of submucosal or
deeper invasive carcinoma.
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51.1 mm (range, 15–100 mm), respectively.
The mucin phenotype analyses are shown in Figure 3
and Additional file 1: Table S3. None of the 7 tumours
in group A expressed gastric phenotypic markers (com-
pletely intestinal phenotype), whereas 8 of 12 tumours
in group B did. Among the 24 tumours of group C,
14 expressed gastric markers, 8 expressed intestinal
markers and 2 had no mucin expression (null phenotype).
The pattern of mucin phenotype expression was signifi-
cantly different between group A and group B or C
(Cochran-Armitage trend test, p = 0.005 and p = 0.03, re-
spectively); but there were no difference between group B
and group C tumours (p = 0.642) and between group A/B
and C tumours (p = 0.147) (Additional file 1: Table S4).
Quantitative PCR (qPCR) results
In qPCR analyses of 8 randomly selected samples using
5 gene primer sets, the aCGH T/R ratios could not be val-
idated in >50% of the 40 comparisons (data not shown).
By comparing the PCR efficiencies between reference
samples before and after WGA, we could demonstrateFigure 3 Phenotypic constitution of tumours in groups A, B, and C. T
(GI) type, intestinal (I) type and null (N) type. The numerals in the colour ba
see the legend for Table 1.biased amplification; however, this bias was dependent on
the examined genes and was reproducible among the
samples (Additional file 2: Figure S1).
Genome-wide CNA patterns
Penetrance-plots of chromosome-level CNAs are shown
for group A/B and group C tumours in Figure 4. Seven
group A and 12 group B tumours included 1 and 2
tumours with losses of 5q and 0 and 1 tumour with gain
of 8q, respectively, whereas 24 group C tumours included
1 tumour with loss of 5q and 8 tumours with gains of 8q.
Gains of 20q were detected in none of group A/B tumours
and 9 group C tumours. Chromosome 21q showed gain in
1 group A/B tumour and losses in 5 group C tumours.
To improve the CNA signal-to-noise ratios, the individ-
ual probe T/R ratios within a specified gene were aver-
aged. The average T/R ratios of 30,098 gene regions were
calculated from 55,023 probes. Based on the average T/R
ratio, the significant CNA frequencies in the total analysed
gene regions, were 33.0% in group A, 43.6% in group B
and 52.2% in group C. The frequencies did not signifi-
cantly differ between groups A and B (Welch’s t-test, p =
0.18) or between groups Cm and Cd (p = 0.28), but they
differed significantly between groups A or B and group C
(p = 0.02 and p = 0.08, respectively).
Cluster analysis
To compare copy-number profiles between mucosal and
deeply invasive parts of individual group Cd tumours,
we added data from deeply invasive part samples, of
which 3 and 13 were obtained from submucosal and
advanced tumours, respectively. The combined data of
mucosal and deeply invasive samples were subjected to
unsupervised cluster analysis with a gene size-dependent
number of genes ranging, from 373 to 9,615 genes. We
found that even the 373 genes with 10 or more probes
fulfilled the neighbouring standard, except for 1 pair of
samples that did not fulfil this standard, irrespective ofhe mucin phenotype is classified into gastric (G) type, gastrointestinal
rs indicate numbers of samples in each group. Regarding Cm and Cd,
Figure 4 Frequency of copy-number alterations (CNAs) at the chromosome level. The percentage of the samples that have CNAs for each
chromosome in the group A/B (a) and group C (b) tumours. Gains and losses are indicated with red and green, respectively.
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a tumour that contained multiple clones (Additional file 3:
Figure S2a).
Of the 5 pairs of concomitant but separately distrib-
uted lesions in the same patients, under the condition of
gene sizes containing up to >6 probes, 3 pairs (A3– A7,
B5 –B12 and A4 – B11) were neighbouring to each other
in the clustering dendrogram (Figure 5 and Additional
file 3: Figure S2b). This genomic copy-number profile
similarity between separate lesions in the same patient
may be associated with the common carcinogenesis envir-
onment but appeared to be less (3 of 5 pairs) than the
similarities between different parts of the same lesion (15
of 16 pairs). In each of the neighbouring pairs (B5 –B12
and A4 – B11), one of the pair was labelled with the
enzymatic method and the other with the ULS method,
showing that there is virtually no difference between the
results of the 2 labelling methods.
All 43 tumours were classifiable into 3 major clusters:
stable (11 tumours), unstable (28 tumours) and inter-
mediate (4 tumours). As shown in Figure 5, the stable
and unstable clusters are characterized by infrequent and
frequent copy-number losses/gains, respectively, reflecting
different degrees of genetic instability. The intermediate
cluster shows intermediate instability. The sample con-
stitution of each was constant under the conditions of
the minimal gene size containing 3–4 probes (Additional
file 4: Figure S3). Based on these findings, we selected the
condition of 2,863 genes containing ≥4 probes (Figure 5).
Under this condition, the unstable cluster included all
group C tumours and 4 of 19 (21%) of groups A/Btumours. The stable cluster comprised solely of group
A/B tumours (4 and 7 in groups A and B, respectively)
and accounted for 11 of the 19 (58%) group A/B tumours.
The relationship of tumour size distribution with histo-
logical grade and mucin phenotype was demonstrated in
each cluster in Figure 6. In the stable cluster, no lesion
exceeded 2 cm in diameter. Among the 3 group A/B
tumour clusters, the tumour size distribution nearly
overlapped, and there was no significant difference in the
mean tumour size, suggesting that tumours in these
clusters may have occurred in parallel and constitute
independent genetic lineages.
For group A/B tumours, the average CNA numbers
were significantly greater in the 4 unstable or 4 inter-
mediate tumours than in the 11 stable tumours, with av-
erages of 15,262, 15,727 and 9,370, respectively (Welch’s
t test, p = 0.004 and p = 0.006, respectively). The CNA
numbers did not differ between the unstable and inter-
mediate clusters (p = 0.79). There were no significant
differences in the histological grade (Figures 5) or mucin
phenotype (Figure 6 and Additional file 1: Table S4)
between the type A/B tumours included in the unstable or
intermediate clusters and the stable cluster. The unstable/
intermediate tumours accounted for 3/7 and 5/12 of the
groups A and B tumours, and the intestinal phenotype for
3/7 and 1/12 of the tumours, respectively.
Genes exhibiting significantly different CNAs among
stable, intermediate and unstable clusters
Of the 14,753 protein-coding genes, we identified a total
of 51 genes exhibiting significantly different copy-numbers
Figure 5 (See legend on next page.)
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Figure 5 Unsupervised-hierarchical cluster analysis using 43 samples and 2,863 genes that contain four or more probes. Genomic
copy-number gains or losses are indicated by red and green squares, respectively, for each gene. The length of the heat map is compressed as a
1:60 ratio for visualization. Samples were classified into three clusters: stable, intermediate, and unstable, which are marked with grey, yellow, and
pink frames, respectively. The numerals under the dendrogram show five pairs of concurrent tumours. The background colours of the sample
names represent morphological categories: light and dark grey indicate non-invasive low-grade and high-grade neoplasms, respectively; light and
dark pink indicate invasive intramucosal tumours and intramucosal parts of submucosal or deeper tumours, respectively.
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these genes and 43 tumour samples, we performed two-
dimensional hierarchical clustering (Figure 7). A sum-
mary of the 51 genes and their significance are shown in
Additional file 1: Table S5. The CNAs of these genes in each
sample are shown in Additional file 5: Figure S4, in which
an association of gene-level CNAs with chromosome-level
CNAs was demonstrated. Eleven out of the 51 genes were
located in 8q, and often showed gains in the unstable
group, associated with the chromosomal gains at 8q
(Additional file 5: Figure S4). The 51 genes also contained
2 genes at 5q, 2 genes at 6p, and 2 genes at 21q thatFigure 6 Relationship of tumour size with mucin phenotypes and his
clusters. Each coloured square, representing a sample, was plotted two di
Light yellow background indicates that samples were not actively collected
margins are the total sample number in each line and column, respectively
and Cd, see the legend for Table 1.showed losses in >50% of the samples in the unstable
group, corresponding to chromosome-level losses except
in 6p.
Discussion
In our previous series of small cancers ranging from 0.2 to
2 cm in diameter, the gastric (G/GI) and intestinal (I) types
accounted for 88% and 4% of cases, respectively [17],
whereas here, in the group B (non-invasive high-grade
neoplasia) and Cm (intramucosal invasive carcinoma) tu-
mours, which ranged from 0.3 to 4.0 cm in diameter, the
G/GI and I types accounted for 70% and 30% of cases,tological grades of tumours in stable, intermediate, and unstable
mensionally according to increasing tumour size and tumour grade.
in these category areas. The numerals on the right side and bottom
. Regarding G, GI, I and N, see the legend for Figure 3. Regarding Cm
Figure 7 Two-dimensional supervised cluster analysis using 43 samples and 51 genes. The cluster showed significantly different copy-numbers
from 5 comparisons: stable vs. intermediate, stable vs. unstable, intermediate vs. unstable, stable/intermediate vs. unstable, and stable vs. unstable/
intermediate. The statistical data from these comparisons are shown in Additional file 1: Table S5. The clustering results of samples were
very similar to those of Figure 5; the samples were classified into 3 clusters: stable, intermediate, and unstable, which are marked with
grey, yellow, and pink frames, respectively.
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size was further enhanced in group Cd (intramucosal part
of submucosal or deeper invasive carcinoma) tumours,
ranging from 1.5 to 10 cm in diameter, in which the G/GI
and I types accounted for 50% and 37.5% of cases, respect-
ively (Figure 3). The decrease in the G/GI-type and coinci-
dent increase in the I-type could reflect a loss of the gastric
phenotype from G and GI, respectively, secondary to an in-
crease in tumour size, which is consistent with the previ-
ously reported notion that a majority of invasive tumours
are derived from the gastric lineage [17] and that the gas-
tric phenotype is lost during tumour progression [18,20].
Additionally, there was no significant difference in I-type
frequency between the group A/B and group C tumours.
These findings indicate that utility of mucin phenotyping
may be limited, with respect to outcome predictions at
later stages of tumour development, because the lineage
markers change during progression. Therefore, in this
study we focused on the aCGH approach.
Validation of candidate genes identified using aCGH is
critical. However, qPCR is difficult to use for validation
purposes because copy-number gains/losses of genomic
DNA are too small to detect; a one-copy loss or gain may
be equivalent to a 0.5- or 1-cycle difference in qPCR. This
may be a reason why we failed to validate more than half of
the aCGH T/R ratios here using qPCR. Another reason is
the high noise level in the data from DNAs extracted from
microdissected FFPE tissues and PCR-amplified. Conse-
quently, we could not comment on the copy-numbers of
individual genes as direct results of aCGH. However, we
noticed that the amplification bias was reproducible among
samples, meaning that the tumour/reference comparison
for each microarray spot (probe) and the comparisons of
the mean copy-numbers among genes could cancel the
amplification bias to some extent. Similarly, copy-number
variations (CNVs), present in both tumour and reference
samples, were also cancelled.
To validate our aCGH data from another aspect, we
compared chromosome-level CNAs detected in this study
to those in previous studies. Recent genomic microarray
data from gastric cancer have shown that gains of chro-
mosomes 8 and 20 are the most frequent chromosome-
level changes [29,30], which was confirmed by our data
(Figure 4b). Gains at 8q and losses at 5q were detected in
a fraction of non-invasive gastric neoplasms [29], which
were reproduced in the present study (Figure 4a), al-
though their frequencies here were lower than those of
the previous report partially due to the higher threshold
for significant CNA in our study.
At the gene level, we compared the copy-number profiles
among the samples by unsupervised hierarchical clustering
using average probe copy-numbers. Larger sized genes, for
which the representative copy-numbers were determined
by averaging a greater number of probe copy-numberswithin the gene, were used to cancel out noise in the gene
copy-number [27]. The reproducibility of genomic copy-
number profiles was also assessed by confirming (1)
neighbouring positions in clustering dendrograms of
samples from identical tumours [27] after adding samples
from deeply invasive parts of the corresponding tumours
and (2) consistency in the sample constitution of each
cluster during repeated clustering with varying gene sizes.
Repeated clustering demonstrated that clustering of the
genes that contain ≥4 probes was optimal and that the
profiles of 2 separate concurrent lesions in a single patient
were less similar than those of different parts of the same
lesion.
Clustering under the optimal condition classified 43
intramucosal gland-forming neoplasms of varying histo-
logical grades into 3 clusters: stable, unstable and inter-
mediate. The unstable cluster may represent a lineage of
poor outcome, consisting of tumours from incipient to
advanced stages because this cluster, but not the stable
cluster, included invasive carcinomas (Figure 6). There
were no significant differences in the histological grades
or mucin phenotypes between the 3 clusters. These find-
ings suggest that progression risk may not be primarily
related to the histological grade or mucin phenotype but
may instead be linked to the lineage-specific, genomic
CNA pattern.
Fifty-one genes with significantly different CNAs
between the 3 clusters were identified (Additional file 1:
Table S5). These CNAs constituted a core profile that
could discriminate between the 3 clusters (Figure 7). The
51 genes include the following biologically relevant genes:
RXRB, a member of the retinoid X receptor family of nu-
clear receptors, which plays a critical role in the regulation
of growth and differentiation in normal and tumour cells
[31], VPS13B, which is mutated in gastric and colorectal
cancers, and in Cohen syndrome with high microsatellite
instability [32] and is coamplified with MYC in breast
cancers [33], and NCOA2, encodes nuclear receptor co-
activator 2, related to the function of nuclear hormone
receptors and amplified or overexpressed in prostate
cancers [34]. As shown in Additional file 5: Figure S4,
CNAs of RXRB were found mostly as gains in the stable
and intermediate groups (14/15), but were often found as
losses or unchanged in the unstable group (24/28), con-
sistent with the tumour-suppressing functions of RXRB.
Copy-numbers of VPS13B and NCOA2 were mostly un-
changed in the stable and intermediate groups (15/15 and
14/15, respectively), but were frequently gained in the un-
stable group (15/28 and 19/28, respectively), consistent
with the oncogenic functions of these genes. Not only
these 2 genes but another 9 out of the 51 were located in
8q, and they often showed gains in the unstable group
(Additional file 5: Figure S4), which may be related to the
8q gain at the chromosome level. At least 12 of the 51
Figure 8 A schematic chart of 3 lineages in the development of
gland-forming gastric neoplasms. This figure is based on Figure 6
and similarly shows the size distribution of 3 lineages: stable,
intermediate and unstable. These lineages may be determined by
the profile of genomic CNAs in the incipient phase of tumour
growth. The growth of stable tumours may be limited in the
mucosa and plateau around the size of 1 cm, whereas the unstable
tumours may largely occur as de-novo carcinomas and partly derive
from intraepithelial neoplasia, accumulate genetic changes and
become intramucosal and deeply invasive tumours. The dotted line
in unstable lineage indicates small de-novo carcinomas, which were
not examined in the present study. The dotted line in intermediate
lineage shows that the outcome of this lineage remains to be
clarified. Regarding Cm and Cd, see the legend for Table 1.
Vo et al. BMC Medical Genomics  (2015) 8:6 Page 11 of 13genes showed CNAs that were parallel to the correspond-
ing chromosome-level CNAs, which were reported previ-
ously [29,30]. These non-random gene-level CNAs, which
are difficult to explain as noises or artefacts, are more sensi-
tively associated with invasive (group C) tumours than are
infrequent chromosome-level changes. The generating
mechanism of CNAs, unrelated to chromosomal changes,
remains to be explained.
Non-invasive neoplasms of intermediate and unstable
lineage had higher levels of genomic instability than
stable-lineage neoplasms (Figure 5). In the stable lineage,
there was no significant size difference between LGNs and
HGNs, whereas in the unstable and intermediate lineages,
LGNs tended to be smaller in size than HGNs (Figure 6).
There was a pair of concurrent LGN and HGN, which
were located in the neighbouring positions in the inter-
mediate cluster, indicating that these tumours can share
highly similar CNAs despite differences in the histological
grade. These findings suggest that a fraction of smaller
LGNs can change to HGNs during tumour development
as demonstrated by follow-up studies [6-15]. In addition,
larger non-invasive neoplasms are more frequently found
to be HGNs, which may explain why HGNs have a higher
risk of progression to invasive carcinomas compared with
LGNs (Figure 8). It remains to be determined if non-
invasive intermediate-lineage neoplasms can progress to
invasive carcinoma and if small carcinomas arising de
novo actually show the unstable CNA profile. More cases
should be examined to clarify these points.
It is unlikely that tumours in the stable cluster stochas-
tically accumulate CNAs to become unstable tumours be-
cause opposing CNAs were detected among the 3 lineages
(Figure 7). Additionally, cell kinetic studies have indicated
that approximately two-thirds to three-quarters of the
natural history of GC has already elapsed in intramu-
cosal tumours of 1 cm in diameter [35]. This means that,
even in small non-invasive tumours, there is sufficient
time to accumulate genomic changes that determine the
potential of tumour aggressiveness, leaving limited oppor-
tunity for further CNA accumulation.
In the near future, development of custom microarrays
for determination of the copy-numbers of essential genes
we extracted may enable us to apply our study to clinical
practice. By applying our approach to endoscopically re-
moved mucosal lesions, the necessity of additional surgical
treatment can be determined. This may give patents to
chance for early treatment of high-risk lesions and relieve
patients with low-risk lesions from unnecessary surgical
excision of stomach.
Conclusions
Relative comparisons of genomic copy-number profiles
by unsupervised hierarchical clustering enabled us to
categorize gastric intramucosal neoplasms according tolineage-specific patterns of CNAs and different degrees
of genomic copy-number instability as stable, unstable,
and intermediate. Since invasive carcinomas were in-
cluded only in the unstable cluster, non-invasive neo-
plasms of the unstable cluster, accounting for 21% of
non-invasive neoplasms, may accumulate genetic changes
in a stochastic manner and progress to invasive GCs,
whereas those of the stable cluster, accounting for 58% of
non-invasive neoplasms may not. This classification was
not significantly correlated with the histological grade,
mucin phenotype or size of non-invasive tumours, but
was consistent with the results of previous long-term
follow-up studies.
Availability and requirements
The microarray data were registered in the GEO data-
base (URL: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE60116).
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Additional file 1: Table S1. Primer sequences used in quantitative PCR.
Table S2a and b. Clinicopathological features of groups A, B and C.
Table S3. Mucin phenotypic expressions in groups A, B, C. Table S4.
Constitution of phenotypic expression in groups (A, B and C) and clusters
(stable, intermediate and unstable). Table S5. List of 51 genes extracted
by t test with Bonferroni correction from 5 different comparisons.
Additional file 2: Figure S1. Plot of PCR cycle number, at which the
PCR products exceed the threshold (Cq). The Cq value profiles of 5 genes
are shown for 8 reference samples before (a) and after (b) whole
genome amplification. The genes used are markers of chromosome 15
and 10 (#51481794-51481853 and # 2681585–72681644, respectively),
MYC, TP53, and MME.
Additional file 3: Figure S2. Two-dimensional supervised cluster
analysis using 43 mucosal and 16 invasive–part samples. To compare the
copy-number profile of mucosal and invasive parts of individual tumours
in the clustering analyses with varying size-dependent gene numbers, 16
samples from invasive parts of Cd tumours were added to the 43 mucosal
samples. Following “Cd”, the sample numbers with and without “m”
indicate intramucosal and extramucosal parts, respectively. (a) Clustering
dendrograms with varying gene numbers, from 9,615 genes containing ≥2
probes to 373 genes containing ≥10 probes. Thick red frames are pairs of
mucosal and invasive samples from identical tumours. These pairs are
consistently neighbouring except for 1 pair of samples marked with
closed red arrows. Of the pairs of concurrent tumours that were located
separately from each other in the single patient and marked with a pair of
numbers under the sample name, the pairs that are located in neighbouring
positions in the dendrogram are marked with thin red frames; those in split
positions are marked with pairs of closed or open black arrows. (b) A heat
map of the clustering that corresponds to the upper right dendrogram of
(a), using 2,863 genes of ≥4 probes. Grey and yellow squares indicate the
samples of the stable and the intermediate clusters, respectively. The
samples without a frame belong to the unstable cluster.
Additional file 4: Figure S3. Two-dimensional supervised cluster
analysis using 43 samples. In this series, sample constitutions of the
clusters were stable under the condition of gene size, containing ≥3-4
probes. The grey, yellow, and red underbars indicate stable intermediate
and unstable clusters, respectively, as defined under this optimal
condition.
Additional file 5: Figure S4. Tumour/reference (T/R) ratios of the 51
candidate genes in the samples of 3 clusters. The T/R ratio of each gene
represents the average T/R ratios of probes within the gene. Significant
copy-number gains and losses are defined as >0.3219 and <−0.3219, and
are marked with pink, and green boxes, respectively. Black frames indicate
the genes mentioned in the text: RXRB, VPS13B, and NCOA2. Regarding
the background colour of “Location” column, pink and green indicate
gains and losses at the chromosome arm level (shown in Figure 4),
respectively. In the column labelled “Association of chromosomal CNAs
with gene CNAs”, positive associations of chromosomal arm-level
CNAs indicated by the colour of the “Location” column with gene-level
CNAs in >50% of samples of the stable, intermediate, or unstable group are
marked with S, I, and U, respectively.
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